Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes–focus on venlafaxine and O-desmethylvenlafaxine

被引：0
|
作者：
Mani Kandasamy
P. Srinivas
Kala Subramaniam
Sandhya Ravi
James John
Radha Shekar
Nuggehally Srinivas
Saral Thangam
机构：
[1] Lotus Labs,Biometrics
[2] Lotus Labs Pvt. Ltd.,Bioanalytical
[3] Lotus Labs Pvt. Ltd.,Clinical
[4] Suramas Biopharm,Drug Development
来源：
European Journal of Clinical Pharmacology | 2010年 / 66卷
关键词：
CYP2D6; Venlafaxine; O-desmethyvenlafaxine; Pharmacokinetics; Bioavailability;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：879 / 887
页数：8
相关论文
共 50 条
  • [11] Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases
    Karlsson, L.
    Zackrisson, A-L
    Josefsson, M.
    Carlsson, B.
    Green, H.
    Kugelberg, F. C.
    PHARMACOGENOMICS JOURNAL, 2015, 15 (02): : 165 - 171
  • [12] Venlafaxine serum levels and CYP2D6 genotype
    Veefkind, AH
    Hafmans, PMJ
    Hoencamp, E
    THERAPEUTIC DRUG MONITORING, 2000, 22 (02) : 202 - 208
  • [13] Venlafaxine oxidation in vitro is catalysed by CYP2D6
    Otton, SV
    Ball, SE
    Cheung, SW
    Inaba, T
    Rudolph, RL
    Sellers, EM
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 41 (02) : 149 - 156
  • [14] Melperone is an inhibitor of CYP2D6 catalyzed O-demethylation of venlafaxine
    Dragicevic, A
    Grözinger, M
    Hiemke, C
    Müller, MJ
    Härtter, S
    PHARMACOPSYCHIATRY, 2002, 35 (04) : IX - IX
  • [15] Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine
    Grözinger, M
    Dragicevic, A
    Hiemke, C
    Shams, M
    Müller, MJ
    Härtter, S
    PHARMACOPSYCHIATRY, 2003, 36 (01) : 3 - 6
  • [16] IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM
    Nahid, N.
    Kanumuri, S.
    Sharma, A.
    Wang, D.
    Johnson, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S74 - S75
  • [17] VENLAFAXINE AND CYP2D6 IN CLINICAL PRACTICE: WORK IN PROGRESS
    Zeppegno, P.
    Rolla, R.
    Dalo, V.
    Ressico, F.
    Parafioriti, A.
    Prosperini, P.
    Vidali, M.
    Bellomo, G.
    Torre, E.
    EUROPEAN PSYCHIATRY, 2010, 25
  • [18] VENLAFAXINE AND CYP2D6 IN CLINICAL PRACTICE: AN OBSERVATIONAL STUDY
    Zeppegno, P.
    Rolla, R.
    Dalo', V.
    Ressico, F.
    Parafioriti, A.
    Prosperini, P.
    Bellomo, G.
    Torre, E.
    EUROPEAN PSYCHIATRY, 2011, 26
  • [19] CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine
    Shams, M. E. E.
    Arneth, B.
    Hiemke, C.
    Dragicevic, A.
    Mueller, M. J.
    Kaiser, R.
    Lackner, K.
    Haertter, S.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2006, 31 (05) : 493 - 502
  • [20] Venlafaxine and CYP2D6 in clinical practice: a case report
    Zeppegno, P.
    Rolla, R.
    Dalo, V.
    Ressico, F.
    Parafioriti, A.
    Prosperini, P.
    Vidali, M.
    Bellomo, G.
    Torre, E.
    JOURNAL OF PSYCHOPATHOLOGY-GIORNALE DI PSICOPATOLOGIA, 2011, 17 (04): : 450 - 452
12345